Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A clinical and economic review of disease-modifying antirheumatic drugs
Autore:
Gabriel, SE; Coyle, D; Moreland, LW;
Indirizzi:
Mayo Clin & Mayo Fdn, Hlth Sci Res, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 Res, Rochester, MN 55905 USA Ottawa Hosp, Loeb Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada OttawaHosp Ottawa ON Canada st, Clin Epidemiol Unit, Ottawa, ON, Canada Univ Alabama, Birmingham, AL USA Univ Alabama Birmingham AL USAUniv Alabama, Birmingham, AL USA
Titolo Testata:
PHARMACOECONOMICS
fascicolo: 7, volume: 19, anno: 2001,
pagine: 715 - 728
SICI:
1170-7690(2001)19:7<715:ACAERO>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS PATIENTS; LOW-DOSE METHOTREXATE; GOLD SODIUM THIOMALATE; TERM PROSPECTIVE TRIAL; FACTOR-ALPHA CA2; DOUBLE-BLIND; PULSE METHOTREXATE; MONOCLONAL-ANTIBODY; FUSION PROTEIN;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
149
Recensione:
Indirizzi per estratti:
Indirizzo: Gabriel, SE Mayo Clin & Mayo Fdn, Hlth Sci Res, 200 1st St SW, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn 200 1st St SW Rochester MN USA 55905 USA
Citazione:
S.E. Gabriel et al., "A clinical and economic review of disease-modifying antirheumatic drugs", PHARMACOECO, 19(7), 2001, pp. 715-728

Abstract

Rheumatoid arthritis is one of the most common chronic systemic inflammatory diseases, affecting approximately 1% of the adult population. Disease-modifying antirheumatic drugs (DMARDs) have been the mainstay of treatment for rheumatoid arthritis when combined with physical therapy and aspirin (acetylsalicylic acid) or nonsteroidal anti-inflammatory drugs. Recently, a number of new biological therapies have been introduced for the treatment of this condition and will have a major impact on the future management of thisdisabling disease. In this review, we summarise data on the efficacy and tolerability of the currently available DMARDs, including gold compounds, antimalarials, penicillamine, cytotoxic drugs (azathioprine and cyclophosphamide), sulfasalazine, methotrexate, leflunomide, cyclosporin, anti-tumour necrosis factor agents, combination therapy and apheresis. A literature review and quality assessment of economic evaluations of DMARDs is presented, illustrating that there has been a paucity of economic evaluations on these agents and showing the variable quality of those studies that are available. The manuscript also addresses the pharmacoeconomic implications of the newagents for rheumatoid arthritis; the need for formal long term economic evaluations in order to determine the cost effectiveness of these costly, buthighly effective, new treatments is emphasised.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 07:23:16